Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs.
| Autor: | Rodby R; Rush University, 1426 W. Washington Blvd, Chicago, IL 60607, USA., Umanath K, Niecestro R, Jackson JH, Sika M, Lewis JB, Dwyer JP |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2015 Jun; Vol. 15 (3), pp. 545-50. Date of Electronic Publication: 2014 Dec 13. |
| DOI: | 10.1586/14737167.2015.995169 |
| Abstrakt: | Background: Ferric citrate (FC) is a new phosphorus binder shown to increase serum iron stores while reducing intravenous iron and erythropoiesis-stimulating agent usage. Such reductions could lower hospitalization rates and associated costs. Methods: Hospitalizations during a Phase III trial were compared between FC and active control (AC). Hospitalization costs were estimated using the 2013 US Renal Data System Annual Data Report. Results: 34.6% of FC patients were hospitalized at least once versus 45.6% of the AC group (risk reduction 24.2%; p = 0.02). There were 181 unique hospitalizations in the FC group versus 239 in the AC group, for a difference of 58 hospitalizations. Total potential savings was US$ 867,622 in hospitalization costs in the FC group. If the hospitalization reduction in our study was applied to the general end-stage renal disease population, this could translate into a savings of US$ 3002/patient/year. Conclusions: Patients receiving FC experienced fewer hospitalizations with the potential for significant savings. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|